Details of the Drug Combination

General Information of Drug Combination (ID: DC2LRXO)

• Drug Combination Name: ATI-17000 + E7820
• Indication: Diffuse intrinsic pontine glioma; Status: Investigative [1]
• Component Drugs:
  ATI-17000 (DMZJVR5): Small molecular drug
  E7820 (DMZRXTL): Small molecular drug
• High-throughput Screening Result:
  Testing Cell Line: DIPG25
  Zero Interaction Potency (ZIP) Score: 25.38
  Bliss Independence Score: 33.77
  Loewe Additivity Score: 0.47
  LHighest Single Agent (HSA) Score: 0.94

Molecular Interaction Atlas of This Drug Combination

Indication(s) of ATI-17000

Disease Entry	ICD 11	Status	REF
Irritable bowel syndrome	DD91.0	Preclinical	[2]

ATI-17000 Interacts with 2 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
Nociceptin receptor (OPRL1)	TTNT7K8	OPRX_HUMAN	Antagonist	[5]
5-HT 3A receptor (HTR3A)	TTPC4TU	5HT3A_HUMAN	Antagonist	[2]

Indication(s) of E7820

Disease Entry	ICD 11	Status	REF
Colorectal cancer	2B91.Z	Phase 2	[3]
Solid tumour/cancer	2A00-2F9Z	Phase 2	[4]

E7820 Interacts with 1 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
Integrin alpha-2 (ITGA2)	TTSJ542	ITA2_HUMAN	Inhibitor	[4]

References

• [1] Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
• [2] Emerging drugs for irritable bowel syndrome. Expert Opin Emerg Drugs. 2006 May;11(2):293-313.
• [3] ClinicalTrials.gov (NCT00309179) A Phase II Study of the Safety and Efficacy of E7820 Plus Cetuximab in Colorectal Cancer, Preceded by a Run-in Study in Advanced Solid Tumors. U.S. National Institutes of Health.
• [4] Phase I study of E7820, an oral inhibitor of integrin alpha-2 expression with antiangiogenic properties, in patients with advanced malignancies. Clin Cancer Res. 2011 Jan 1;17(1):193-200.
• [5] Nocistatin and nociceptin given centrally induce opioid-mediated gastric mucosal protection. Peptides. 2008 Dec;29(12):2257-65.